businesswire.comNovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal10 months ago
businesswire.comNovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders11 months ago
businesswire.comProminent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brandabout 1 year ago
businesswire.comNovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Priceabout 1 year ago
businesswire.comNovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assetsabout 1 year ago
finance.yahoo.comEyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officerabout 1 year ago
businesswire.comNovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024over 1 year ago
businesswire.comNovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Optionover 1 year ago
CashuNovaBay Pharmaceuticals Sells Avenova Business for $11.5 Million Amid Strategic Restructuring10 months ago
CashuNovaBay Pharmaceuticals (NBY) Seeks Stockholder Approval for Avenova Sale and Liquidation Plans11 months ago
CashuNovaBay Pharmaceuticals Proposes Avenova Sale and Liquidation to Enhance Shareholder Value12 months ago